Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Service, by Application, by region, and Competition, 2020-2030F

Description

The Global Nucleic Acid Therapeutics CDMO Market, valued at USD 11.52 Billion in 2024, is projected to experience a CAGR of 8.29% to reach USD 18.58 Billion by 2030. Nucleic acid therapeutics represent a distinct class of pharmaceutical products utilizing genetic material, such as DNA or RNA, to modulate gene expression for therapeutic purposes, encompassing modalities like antisense oligonucleotides, small interfering RNAs, and messenger RNAs. The global Contract Development and Manufacturing Organization (CDMO) market for these therapeutics is primarily driven by expanding biopharmaceutical research and development investments, the increasing pipeline of novel nucleic acid drug candidates, and the critical need for specialized manufacturing capabilities.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 11.52 Billion
Market Size 2030	USD 18.58 Billion
CAGR 2025-2030	8.29%
Fastest Growing Segment	RNA-based Therapies
Largest Market	North America

Key Market Drivers

The expanding therapeutic pipeline for nucleic acid modalities significantly underpins the growth of the Contract Development and Manufacturing Organization market. The increasing number of novel drug candidates, including antisense oligonucleotides, messenger RNAs, and small interfering RNAs, necessitates specialized expertise and infrastructure for their development and large-scale production. These modalities offer targeted approaches for previously intractable diseases, creating a robust demand for outsourced services. For example, according to the article "Advancements in clinical RNA therapeutics: Present developments and prospective outlooks" published in PMC in April 2024, the exploration of antisense oligonucleotide-based therapies alone has progressed through 100 Phase I trials, with 25% of these advancing to Phase II or III trials, indicating a substantial volume of candidates requiring further development and manufacturing support. This progression through clinical stages directly translates into a requirement for advanced process development, analytical testing, and Good Manufacturing Practice compliant production.

Key Market Challenges

The inherent complexity and scalability issues associated with manufacturing advanced nucleic acid therapeutics, particularly in consistently achieving required quality and purity standards at commercial production volumes, represent a significant impedance to the growth of the global Contract Development and Manufacturing Organization (CDMO) market. These modalities often require specialized equipment, highly controlled environments, and intricate purification processes, leading to elevated operational costs and extended development timelines for CDMOs. Such manufacturing intricacies limit the capacity of CDMOs to efficiently process the increasing pipeline of novel drug candidates, creating bottlenecks within the supply chain.

Key Market Trends

Strategic Capacity Expansion Initiatives represent a significant trend as Contract Development and Manufacturing Organizations invest heavily to meet the escalating demand for nucleic acid therapeutics. This involves constructing new facilities, expanding existing operational footprints, and integrating advanced equipment to enhance overall manufacturing throughput and capabilities. Such proactive investments are crucial for ensuring the reliable and timely supply of critical drug substances and products, thereby supporting the clinical and commercial progression of novel therapies. For instance, according to a BioSpace report in January 2024, Lonza projected flat sales for the year but confirmed mid-term guidance and reported full-year 2023 sales of $7.75 billion, driven by strong performance in its Biologics and Small Molecules divisions, highlighting sustained investment in its manufacturing network. In October 2024, Lonza also completed the acquisition of a large-scale biologics facility in Vacaville, US, from Roche, further expanding its capabilities and dedicating CHF 1.4 billion of CapEx in 2024 towards its organic investment program for future growth across technologies.

Key Market Players

Catalent Inc.
Thermo Fisher Scientific Inc.
Lonza Group Ltd.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Charles River Laboratories International, Inc.
Eurofins Genomics
Sirion Biotech GmbH
Oxford Biomedica Plc.
Danaher Corp.

Report Scope:

In this report, the Global Nucleic Acid Therapeutics CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nucleic Acid Therapeutics CDMO Market, By Type:

Gene Therapy
RNA-based Therapies

Nucleic Acid Therapeutics CDMO Market, By Service:

Process Development & Optimization
Manufacturing Services
Analytical and Quality Control Services
Others

Nucleic Acid Therapeutics CDMO Market, By Application:

Oncology
Genetic Disorders
Infectious Diseases
Others

Nucleic Acid Therapeutics CDMO Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nucleic Acid Therapeutics CDMO Market.

Available Customizations:

Global Nucleic Acid Therapeutics CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nucleic Acid Therapeutics CDMO Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Gene Therapy, RNA-based Therapies)
- 5.2.2. By Service (Process Development & Optimization, Manufacturing Services, Analytical and Quality Control Services, Others)
- 5.2.3. By Application (Oncology, Genetic Disorders, Infectious Diseases, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Nucleic Acid Therapeutics CDMO Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Service
- 6.2.3. By Application
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Nucleic Acid Therapeutics CDMO Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Service
    - 6.3.1.2.3. By Application
- 6.3.2. Canada Nucleic Acid Therapeutics CDMO Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Service
    - 6.3.2.2.3. By Application
- 6.3.3. Mexico Nucleic Acid Therapeutics CDMO Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Service
    - 6.3.3.2.3. By Application

7. Europe Nucleic Acid Therapeutics CDMO Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Service
- 7.2.3. By Application
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Nucleic Acid Therapeutics CDMO Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Service
    - 7.3.1.2.3. By Application
- 7.3.2. France Nucleic Acid Therapeutics CDMO Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Service
    - 7.3.2.2.3. By Application
- 7.3.3. United Kingdom Nucleic Acid Therapeutics CDMO Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Service
    - 7.3.3.2.3. By Application
- 7.3.4. Italy Nucleic Acid Therapeutics CDMO Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Service
    - 7.3.4.2.3. By Application
- 7.3.5. Spain Nucleic Acid Therapeutics CDMO Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Service
    - 7.3.5.2.3. By Application

8. Asia Pacific Nucleic Acid Therapeutics CDMO Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Service
- 8.2.3. By Application
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Nucleic Acid Therapeutics CDMO Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Service
    - 8.3.1.2.3. By Application
- 8.3.2. India Nucleic Acid Therapeutics CDMO Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Service
    - 8.3.2.2.3. By Application
- 8.3.3. Japan Nucleic Acid Therapeutics CDMO Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Service
    - 8.3.3.2.3. By Application
- 8.3.4. South Korea Nucleic Acid Therapeutics CDMO Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Service
    - 8.3.4.2.3. By Application
- 8.3.5. Australia Nucleic Acid Therapeutics CDMO Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Service
    - 8.3.5.2.3. By Application

9. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Service
- 9.2.3. By Application
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Nucleic Acid Therapeutics CDMO Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Service
    - 9.3.1.2.3. By Application
- 9.3.2. UAE Nucleic Acid Therapeutics CDMO Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Service
    - 9.3.2.2.3. By Application
- 9.3.3. South Africa Nucleic Acid Therapeutics CDMO Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Service
    - 9.3.3.2.3. By Application

10. South America Nucleic Acid Therapeutics CDMO Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Service
- 10.2.3. By Application
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Nucleic Acid Therapeutics CDMO Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Service
    - 10.3.1.2.3. By Application
- 10.3.2. Colombia Nucleic Acid Therapeutics CDMO Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Service
    - 10.3.2.2.3. By Application
- 10.3.3. Argentina Nucleic Acid Therapeutics CDMO Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Service
    - 10.3.3.2.3. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Nucleic Acid Therapeutics CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Catalent Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific Inc.
15.3. Lonza Group Ltd.
15.4. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
15.5. Charles River Laboratories International, Inc.
15.6. Eurofins Genomics
15.7. Sirion Biotech GmbH
15.8. Oxford Biomedica Plc.
15.9. Danaher Corp.